Hyundai Bioscience said its board resolved on October 23, 2026 to convene an extraordinary general meeting of shareholders on December 9, 2026.

Hyundai Bioscience filed a disclosure on October 23, 2026 saying it will hold an extraordinary general meeting of shareholders on December 9, 2026 at 10 a.m. at its headquarters on the 2nd floor in Gimcheon, North Gyeongsang Province. The company said the meeting is to handle the director election proposal and other items that failed at the March 2026 annual general meeting. Shareholders are expected to consider the election of Kim Jin-seok as an independent director, the election of Cho Yong-ho as a full-time auditor, and approval of the director and auditor pay limits.

1. 01

   The company said the extraordinary meeting is being convened to handle the director election proposal and other items that failed at the annual general meeting on March 26, 2026 because the quorum was not met.

2. 02

   The agenda items are the election of Kim Jin-seok as an independent director, the election of Cho Yong-ho as a full-time auditor, approval of the director pay limit, and approval of the auditor pay limit, totaling 4 items.

3. 03

   The director and auditor pay limits were each reduced from the amounts proposed at the annual general meeting, which were KRW 2 billion and KRW 200 million.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

General meeting date and time

December 9, 2026 10 a.m.

Record date for voting rights

November 9, 2026

Director pay limit (ᵀ27th term)

KRW 500 million

Auditor pay limit (27th term)

KRW 80 million

Filing facts

Filing type

Shareholders Meeting

Report name

Resolution to Convene a Shareholders Meeting (Extraordinary General Meeting)

Filed

Oct 23, 2026

Receipt number

20261023900716